Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
John F. Crowley, insider at Amicus Therapeutics
John F. Crowley Insider Alerts

Get notified the next time John F. Crowley buys or sells Amicus Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

John F. Crowley Insider Information

John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, “The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children.” The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame and the Wall Street Journal CEO Council. Currently, John serves as a member of the Intellia Therapeutics, Inc. Board of Directors. He is the former National Chairman of the Make-A-Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.

What is John F. Crowley's net worth?

The estimated net worth of John F. Crowley is at least $9.24 million as of August 5th, 2021. Mr. Crowley owns 884,345 shares of Amicus Therapeutics stock worth more than $9,241,405 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Crowley may own. Learn More.

What is John F. Crowley's salary?

As the CEO of Amicus Therapeutics, Inc., Mr. Crowley earned a total compensation package of $11,315,124.00 in 2020. Mr. Crowley earned a salary of $719,514.00, a bonus of $514,800.00, stock awards of $5,479,971.00, options awards of $2,492,491.00, and other compensation of $825,505.00.

How do I contact John F. Crowley?

The corporate mailing address for Mr. Crowley and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]

Has John F. Crowley been buying or selling shares of Amicus Therapeutics?

John F. Crowley has not been actively trading shares of Amicus Therapeutics during the past quarter. Most recently, John F. Crowley sold 37,000 shares of the business's stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $10.03, for a transaction totalling $371,110.00. Following the completion of the sale, the chief executive officer now directly owns 884,345 shares of the company's stock, valued at $8,869,980.35.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (COO), Bradley Campbell (COO), John Crowley (CEO), John Crowley (CEO), Margaret Mcglynn (Director), Samantha Prout (Insider), and Burke Whitman (Director).

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, Amicus Therapeutics insiders bought shares 9 times. They purchased a total of 40,605 shares worth more than $389,132.70. During the last year, insiders at the biopharmaceutical company sold shares 37 times. They sold a total of 667,220 shares worth more than $9,920,506.00. The most recent insider tranaction occured on December, 1st when COO Bradley L Campbell sold 10,515 shares worth more than $115,665.00. Insiders at Amicus Therapeutics own 2.5 % of the company.

Information on this page was last updated on 12/1/2021.

John F. Crowley Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/5/2021Sell37,000$10.03$371,110.00884,345View SEC Filing Icon  
See Full Table

John F. Crowley Buying and Selling Activity at Amicus Therapeutics

This chart shows John F. Crowley's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.
Read More

Today's Range

Now: $10.45
Low: $10.32
High: $11.21

50 Day Range

MA: $11.06
Low: $9.55
High: $12.44

2 Week Range

Now: $10.45
Low: $8.60
High: $25.39


1,747,158 shs

Average Volume

2,134,637 shs

Market Capitalization

$2.91 billion

P/E Ratio


Dividend Yield



Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!